
    
      Single arm phase II trial of combination therapy bortezomib, DICE, and Rituximab in patients
      with relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma (NHL)

      VIPER chemotherapy will be administered every 28 days at the following doses:

        -  Dexamethasone 40 mg IV days 1-4

        -  Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4

        -  Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)

        -  Cisplatin 25 mg IV days 1-4

        -  Etoposide 100 mg/m2 CIVI over 24 hours days 1-4

        -  Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)

        -  VELCADE 1.5 mg/m2 on days 2 and 5
    
  